IMR Press / FBE / Volume 3 / Issue 3 / DOI: 10.2741/E296

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


EGFR genomic alterations in cancer: prognostic and predictive values

Show Less
1 Department of Surgical and Oncological Sciences, Section of Medical Oncology, University of Palermo, Palermo
2 Medical and Experimental Oncology Unit, Cancer Institute, Giovanni Paolo II, Bari, Italy
3 Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy
4 Department of Surgical and Oncological Sciences, Section of General and Thoracic Surgery, University of Palermo, Palermo, Italy
5 Department of Medical Biotechnologies and Legal Medicine, University of Palermo, Palermo, Italy
6 Department of General Surgery, Urgency, and Organ Transplantation, University of Palermo, Italy
7 Chair and Unit of Hematology transplant, Azienda Ospedaliera Universitaria Policlinico P. Giaccone, Palermo, Italy

*Author to whom correspondence should be addressed.


Front. Biosci. (Elite Ed) 2011, 3(3), 879–887;
Published: 1 June 2011

The role of EGFR in cancer development and progression has been recognized for long time in a variety of human malignancies including lung, head and neck, colon, breast, ovary and glioma. Recently its role as a target of antineoplastic agents has also been identified and a variety of EGFR-targeted drugs is already being used in a clinical setting and others are at present under investigation. Many data involving EGFR protein expression are now available for the choice of anti-EGFR monoclonal antibodies in colorectal cancer and with regard to EGFR gene mutations for the choice of tyrosine kinase inhibitors in lung cancer. Other EGFR-related molecular factors, including the EGFR gene copy number, are currently under investigation. This review summarizes both preclinical and clinical available data regarding EGFR genomic alterations as prognostic and predictive factors.

Monoclonal Antibodies
Tyrosine Kinase Inhibitors
Back to top